Table 3.
Amubarvimab and romlusevimab effectively neutralize most live viruses tested.
| Lineage | WHO naming convention | Key amino acid substitutions in RBD | Amubarvimab | Romlusevimab | Amubarvimab + Romlusevimab |
|---|---|---|---|---|---|
| Average fold-change in IC50 relative to SARS-CoV-2 wild-type USA-WA1/2020 | |||||
| USA-WA1/2020 | NA | None | 1.0 | 1.0 | 1.0 |
| B.1.1.7-CA | Alpha | N501Y | 0.5 | 0.5 | 0.4 |
| B.1.1.7-PHE | Alpha | N501Y | 0.2 | 0.3 | 0.2 |
| B.1.351 | Beta | E484K, N501Y | 0.7 | 7.0 | 1.4 |
| Average fold-change in IC50 relative to SARS-CoV-2 wild-type Beta/Shenzhen/SZTH-003/2020 | |||||
| Beta/Shenzhen/SZTH-003/2020 | NA | None | 1.0 | 1.0 | 1.0 |
| B.1.351 | Beta | K417N, E484K, N501Y | 0.4 | 15.3 | 0.4 |
| B.1.617.2 | Delta | L452R, T478K | 2.1 | >320.5 | 2.9 |
| Neutralization data of amubarvimab and romlusevimab together against live viruses of Omicron sub-lineages and wild-type WA1/2020 | |||||
| SARS-CoV-2 | Sub-lineages | Key amino acid substitutions in RBD | Neut99 of amub. + roml. (μg/ml) | Fold-change in Neut99 relative to wild-type | |
| Wild-type | WA1/2020 (CDC) | None | 0.16 | 1.0 | |
| B.1.1.529 | BA.1 | G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H | 0.63 | 4.0 | |
| BA.1.1 | G339D, R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H | >10.00 | >64.0 | ||
| BA.2 | G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H | 2.50 | 16.0 | ||
| BA.2.12.1 | G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452Q, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H | 0.47 | 2.9 | ||
| BA.4/5 | G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H | 0.94 | 5.9 | ||